Ispire Technology Inc. — Form 10-Q Summary
Period: Quarter and nine months ended March 31, 2023; balance sheet compared with June 30, 2022. Although the request identifies “2022 Q3,” this filing covers fiscal 2023 third-quarter results. Financial statements are unaudited.
Business context and financial performance
Ispire develops and sells tobacco vaping products internationally and cannabis vaping hardware primarily in the United States. It operates through subsidiaries and relies on related-party Shenzhen Yi Jia for substantially all product purchases.
| Metric | Three months ended March 31, 2023 | Nine months ended March 31, 2023 |
|---|---|---|
| Revenue | $24.1 million, up 26.9% year over year | $83.0 million, up 25.3% |
| Gross profit / margin | $4.5 million / 18.7% (15.7% prior year) | $14.5 million / 17.4% (15.5% prior year) |
| Operating loss | $3.5 million | $5.1 million |
| Net loss | $3.1 million; $0.06 per share | $6.1 million; $0.12 per share |
| Operating cash flow | $2.3 million provided for nine months, versus $24.0 million used in the prior-year period |
For the nine months, tobacco vaping revenue was $59.6 million and cannabis vaping revenue was $23.4 million. Revenue growth reflected increased tobacco sales in Europe and increased cannabis sales in the United States. Gross-margin improvement was mainly attributed to higher-margin cannabis product mix and volume-related economies of scale. Tobacco product margins were broadly steady.
Financial position, liquidity and cash flow
- At March 31, 2023, cash and cash equivalents were $24.0 million, plus a $9.6 million certificate of deposit classified as a held-to-maturity investment and maturing February 8, 2024.
- Current assets were $63.6 million and current liabilities $58.4 million, leaving working capital of $5.2 million, down from $10.5 million at June 30, 2022.
- Total liabilities were $62.0 million. The filing reports no conventional borrowings; lease liabilities were $4.5 million, including $0.9 million current and $3.6 million non-current.
- Cash fell $50.4 million over the nine months. Financing used $42.6 million, chiefly repayment of $40.5 million in related-party advances and $3.4 million of dividend payments. Investing used $10.1 million, primarily for the certificate of deposit.
- Operating cash generation included a $13.7 million increase in accounts payable, partly offset by a $9.3 million increase in accounts receivable. Accounts payable to related party Shenzhen Yi Jia rose to $56.0 million.
- Equity increased to $80.0 million, including a $74.3 million capital contribution reflecting transfer of intellectual property from the chairman and related parties.
Material changes and unusual items
- Operating expenses more than doubled year over year: to $8.0 million for the quarter and $19.6 million for nine months. Higher general and administrative costs included added staffing, bad-debt charges, amortization of transferred intellectual property, IPO-related professional fees, and facility-related rent and warehouse costs.
- The company recorded $2.2 million of accounts-receivable impairment for the nine-month period; the quarter included a $1.8 million bad-debt expense. Management cited disputed customer accounts tied to delayed shipments.
- Intellectual property transferred in September 2022 was recorded at $74.3 million. At March 31, net intangible assets were $72.7 million, including $43.4 million of indefinite-lived trademarks and $29.4 million of patents.
- In April 2023, after quarter-end, the company completed an IPO of 3.105 million shares at $7.00 per share, producing approximately $18.5 million in net proceeds. The filing stated these proceeds, cash on hand and operating cash flows were expected to meet working-capital needs for the next 12 months.
Outlook, risks and controls
Management plans to develop manufacturing operations in California and Vietnam to diversify supply and address disruption and cost risks, but says it lacks manufacturing experience and cannot assure timely launch, efficient operation, or cost savings. Until facilities are established, it expects continued reliance on Shenzhen Yi Jia. Management also anticipates higher public-company expenses.
- Regulatory uncertainty is material. The company stopped marketing tobacco vaping products in the United States and reported no U.S. tobacco vaping sales in the nine months. Its U.S. cannabis business could be significantly affected by new restrictions; cannabis remains subject to complex state and federal legal issues.
- One U.S. ENDS product has a PMTA pending; the FDA could reject it. The filing describes regulatory restrictions across markets and the potential impact of changes to vaping rules.
- Supply-chain disruption, Chinese policy changes, component shortages, customer collections, related-party supplier dependence, foreign-exchange movements, and broader economic conditions remain risks.
- Management said disclosure controls and procedures were effective as of March 31, 2023. It described ongoing work to build internal financial controls and staffing as the company transitioned to public reporting.
Most important facts for investors to verify
- Whether the $56.0 million related-party supplier payable, supplier concentration, and payment terms create material liquidity or operational exposure.
- The collectability and aging of receivables, including disputed balances and the adequacy of the recorded allowance.
- Whether the planned California and Vietnam manufacturing facilities are funded, permitted, staffed, and progressing, and whether they can reduce dependence on China.
- The status and commercial implications of the pending PMTA and other applicable tobacco and cannabis regulations.
- Actual cash use after the IPO, public-company cost increases, and progress toward profitability given rising operating expenses.
- The cover page marks “No” for having filed all required reports during the preceding 12 months; investors should confirm the reason and any reporting implications.